Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
This is an Open Access article published by Multidisciplinary Digital Publishing Institute in International Journal of Molecular Sciences, available online: https://dx.doi.org/10.3390/ijms231911145
Abstract
Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.
This paper has been withdrawn.